Hims & Hers (HIMS) is presented as a high-conviction buying opportunity, viewed as a "steal" in the digital health sector due to its strong performance and low stock price. For a deep-value play, consider CoreMedics (CRMD), an anti-infection company with projected 120% revenue growth that is described as "super special" cheap. Despite its large size, NVIDIA (NVDA) is considered undervalued on a growth-adjusted basis, making its recent pullback a potential entry point. The Real Brokerage (REAX) offers a high-growth investment in the real estate sector, seen as "ridiculously cheap" relative to its massive revenue projections. For a short-term trade, Oscar Health (OSCR) is highlighted as a "swing trade" opportunity based on its extremely low valuation and near-term catalysts.

Sezzle (SEZL)

• A Buy Now, Pay Later (BNPL) company that is described as a smaller player but with higher growth than competitors like Afterpay or Affirm.
• The stock price has dropped significantly from a recent high of $170 to its current price of $70.
• The speaker uses a custom valuation metric (Enterprise Value / Gross Profit / Revenue Growth) which is 0.15 for Sezzle. The speaker considers anything under 0.3 to be "quite cheap".
• It scores very high on the Rule of 40, a venture capital metric for high-growth companies, with a score of 111.

Takeaways

• The speaker has a bullish sentiment, viewing the stock as "very cheap" after its recent price drop.
• It's an investment in the high-growth BNPL space, but through a smaller, faster-growing company compared to the market leaders.
• The strong Rule of 40 score suggests it has a good balance of growth and profitability (or a path to it), which is a positive sign for potential investors.

The Real Brokerage (REAX)

• A real estate brokerage platform that is growing very quickly despite a difficult real estate market.
• Its growth strategy involves attracting top-performing real estate agents from traditional brokerages with a more favorable commission structure. After an agent hits a certain fee threshold, the company stops taking a cut of their commissions for the year.
• The platform is app-based, making it cheaper to operate than traditional firms.
• Valuation is considered very low, with an Enterprise Value / Gross Profit / Revenue Growth metric of 0.1.
• The company has a Rule of 40 score of 53.
• While margins are low due to the nature of the real estate sector, its Enterprise Value to Sales ratio is described as "ridiculously cheap." The company has an $800 million market cap but is projected to make $1.8 billion in revenue in the next 12 months.

Takeaways

• The speaker is bullish on REAX, highlighting its rapid growth and disruptive business model in the real estate industry.
• It represents a play on a modern, tech-driven brokerage that is successfully taking market share from legacy players.
• The stock appears significantly undervalued based on its revenue, even if its profit margins are thin.

Hims & Hers Health (HIMS)

• A digital health company described as a "digital doctor in a digital pharmacy without insurance with AI."
• The speaker is extremely bullish and "cannot possibly understand" why the stock is trading so cheaply, viewing it as a "steal."
• The company's model of not accepting insurance allows it to move much faster and be more innovative than competitors.
• The valuation metric (Enterprise Value / Gross Profit / Revenue Growth) is 0.11, which the speaker considers "heavily undervalued."
• The speaker believes HIMS has the potential to become a "mini big tech company" in the healthcare sector due to its strong execution and expansion into new areas.

Takeaways

• The speaker sees a major dislocation between the company's strong performance and its low stock price, suggesting a significant buying opportunity.
• HIMS is presented as a high-conviction, long-term investment in the future of healthcare, leveraging AI and a direct-to-consumer model to bypass the slow, traditional insurance system.

LifeMD (LFMD)

• A digital health company often called "Baby HIMS." It is a direct competitor to Hims & Hers.
• The stock is described as "way too cheap" and is valued at about four times cheaper than HIMS based on the speaker's metric (a score of 0.027 for LFMD vs. 0.11 for HIMS).
• It is growing slower than HIMS (at 24% revenue growth) which the speaker attributes to its decision to work with insurance companies. This creates friction, such as when customers are prescribed a GLP-1 drug only to find out weeks later that their insurance won't cover it.
• The speaker notes that LFMD does not execute as quickly as HIMS, citing delays in launching a new menopause offering.
• The recent sale of its software business, WorkSimply, is expected to give Wall Street a clearer picture of the core business.

Takeaways

• LFMD is presented as a deep-value play in the digital health space. It is much cheaper than its main competitor, HIMS.
• The investment thesis is that the stock is too cheap to ignore, despite its slower growth and execution compared to HIMS.
• An investor might choose LFMD over HIMS if they are looking for a cheaper entry point into the sector and are willing to accept slower execution in exchange for a lower valuation.

"Nebius" (NBIS)

• The speaker discusses a company they call "Nebius" with the ticker NBIS. They express confusion over its low price, noting it has dropped from $1.35 to $0.87.
• The speaker claims the company signed two enormous deals for cloud GPUs: one with Microsoft for $19.4 billion and one with Meta for $3 billion.
• The company is said to own a 28% stake in ClickHouse, a data analytics company used by Tesla, and fully owns AVRide, a self-driving technology company.
• The speaker views it as a "mini-big tech company" with "enormous upside" that is not reflected in its $20 billion valuation.

Takeaways

• The speaker is extremely bullish, believing the market is completely mispricing the company given its massive contracts and valuable assets.
• The investment thesis is based on exposure to the high-demand cloud GPU market through major deals with big tech, as well as valuable stakes in other promising tech companies like ClickHouse and AVRide.
• Note for Investors: The deals and valuation mentioned by the speaker are widely associated with the private company CoreWeave, not the publicly traded company Nuburu Inc. (NBIS). Investors should perform their own due diligence to clarify this significant discrepancy.

NVIDIA (NVDA)

• Despite being one of the world's most valuable companies, the speaker calls NVDA the "cheapest of the Mag 7" on a growth-adjusted basis.
• Its valuation metric (Enterprise Value / Gross Profit / Revenue Growth) is 0.43. For comparison, the speaker notes it is cheaper than Meta and Amazon by this measure.
• The Rule of 40 score is an extremely high 128.
• The speaker uses a conservative revenue growth estimate of 69%, but suggests it could be over 100% based on CEO Jensen Huang's commentary about future demand.
• The speaker does not understand the stock's recent sell-off, believing the initial bullish reaction that drove the price up was the correct one.

Takeaways

• The speaker is very bullish on NVIDIA, arguing that even at its massive size, its incredible growth rate makes it undervalued compared to its big-tech peers.
• The insight is that investors shouldn't be scared off by the high stock price or large market cap, as the underlying growth is so strong that it justifies a higher valuation.

Oscar Health (OSCR)

• An insurance company described as "dirt cheap," with an Enterprise Value / Gross Profit / Revenue Growth metric of 0.026.
• The speaker believes its revenue growth will be "meaningfully higher" than the guided 25% because the company is significantly raising its insurance premiums on the ACA marketplace.
• The company's forward guidance is conservative as it does not include any potential extension of ACA subsidies, which would be an added tailwind.
• Risk Factor: The speaker is not a fan of insurance companies for long-term holds due to heavy regulation and political risk.

Takeaways

• The speaker views OSCR as a short-term "swing trade" rather than a long-term investment.
• The investment thesis is to capitalize on the stock's extremely low valuation and the potential for near-term catalysts like higher-than-expected revenue from premium hikes. The speaker's personal goal would be to sell after the stock doubles.

CoreMedics (CRMD)

• An anti-infection/antifungal company whose main product helps prevent infections for dialysis patients.
• A key advantage is that its product saves money for Medicare, which the speaker believes reduces the risk of regulators cutting reimbursement for it.
• The stock is highlighted for being extremely cheap, with an Enterprise Value / Gross Profit / Revenue Growth metric of 0.034.
• It is described as being about 10 times cheaper than a peer like TransMedics (TMDX).
• The company has outstanding financial metrics: projected 120% revenue growth, 41% EBITDA margin, and a Rule of 40 score of 161.

Takeaways

• The speaker is very bullish, loving both the innovative product and, more importantly, the "super special" cheap valuation.
• This is presented as an opportunity to invest in an innovative and cash-printing health-tech company at a fraction of the price of its peers. The combination of high growth, high profitability, and a low valuation is extremely rare.

Zeta Global (ZETA)

• A marketing-focused Software-as-a-Service (SaaS) company.
• Its latest product, Athena, is described as a "mini Palantir for marketing," suggesting powerful AI and data capabilities.
• The company is growing fast (nearly 30% revenue growth), is profitable (21% EBITDA margin), and has a Rule of 40 score of 49%.
• The speaker sees it as "way too cheap" for a software company with these metrics, with a market cap of around $4.5 billion.
• The speaker believes it could eventually grow to compete with giants like Salesforce (CRM).

Takeaways

• The speaker is bullish, highlighting ZETA as a rare, undervalued opportunity in the typically expensive software sector.
• The investment thesis is based on getting in early on a fast-growing, profitable marketing platform with powerful AI technology that could have a much larger footprint in the future.

On Holdings (ONON)

• A Swiss company that makes high-end running shoes.
• The company is seen as a major disruptor, taking significant market share from legacy brands like Nike.
• It has strong financial characteristics: high gross margins (62%), strong forward revenue growth (31%), and a Rule of 40 score of 45.
• The valuation metric (Enterprise Value / Gross Profit / Revenue Growth) is 0.22, which the speaker considers "dirt cheap."

Takeaways

• The speaker is bullish and views ONON as a much more interesting investment in the apparel sector than Nike or Lululemon.
• It is a pure-play investment in a high-growth, high-margin brand that is successfully challenging the industry leaders. The speaker notes that a recent price of $35 was a buying opportunity before the stock rebounded.

MercadoLibre (MELI)

• Described as the "Amazon of Latin America," it is the dominant e-commerce platform in the region.
• Beyond e-commerce, it has a large and successful fintech and lending division, making it a "super app" for Latin America.
• The stock is characterized as "cozy," stable, and low-volatility despite its fast growth (36%).
• The speaker attributes its stability partly to its high share price (around $2,000), which reduces speculative options activity.
• It acts as a stabilizing "beacon for the portfolio" during volatile market days.

Takeaways

• The speaker is bullish, recommending MELI as a stable, long-term anchor for a growth-oriented portfolio.
• It offers a unique combination of high growth (from dominating the Latin American e-commerce and fintech markets) and lower volatility compared to other high-growth tech stocks.